SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ZANTE GREG

(Last)

(First)

(Middle)

C/O VIKING THERAPEUTICS, INC.

12340 EL CAMINO REAL, SUITE 250

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/04/2021

3. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.00001 per share	21,896⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	03/31/2021⁽²⁾	03/31/2030	Common Stock	17,000	$4.68	D
Stock Option (Right to Buy)	01/03/2021⁽³⁾	01/03/2030	Common Stock	51,000	$7.77	D
Stock Option (Right to Buy)	07/31/2020⁽⁴⁾	07/31/2029	Common Stock	42,000	$7.69	D
Stock Option (Right to Buy)	01/15/2020⁽⁵⁾	01/15/2029	Common Stock	32,000	$8.52	D
Stock Option (Right to Buy)	08/31/2018⁽⁶⁾	08/31/2028	Common Stock	7,500	$13.07	D
Stock Option (Right to Buy)	⁽⁷⁾	04/30/2028	Common Stock	7,500	$4.12	D
Stock Option (Right to Buy)	⁽⁸⁾	01/19/2028	Common Stock	12,250	$4.65	D

Explanation of Responses:

1. Includes (a) 2,334 shares subject to a restricted stock unit award ("RSU") of common stock that was granted on January 19, 2018 under the Issuer's 2014 Equity Incentive Plan, of which one-third of the original 7,000 shares subject to the RSU vested or shall vest on each one year anniversary of the grant date of the award; and (b) 15,111 shares subject to an RSU of common stock that was granted on January 3, 2020 under the Issuer's 2014 Equity Incentive Plan, of which one-third of the original 22,666 shares subject to the RSU vested or shall vest on each one year anniversary of the grant date of the award.

2. 25% of the shares subject to the option will vest on each one year anniversary of the grant date of March 31, 2020.

3. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date of January 3, 2020.

4. One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date of July 31, 2019.

5. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date of January 15, 2019.

6. One-third of the shares subject to the option vested on the grant date and one-third of the shares subject to the option vested on each one year anniversary of the grant date of August 31, 2018.

7. 25% of the original 30,000 shares subject to the option vested on the grant date and 25% of the original 30,000 shares subject to the option vested or will vest on each one year anniversary of the grant date of April 30, 2018.

8. 25% of the original 24,500 shares subject to the option vested or will vest on each one year anniversary of the grant date of January 19, 2018.

Remarks:

	/s/ Michael Morneau, as Attorney-in-Fact	01/06/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.